🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Using geometric deep learning to identify targets, protein surfaces to match targets to ligases, and virtual screening to design MGDs, our integrated data moat and AI algorithms guide our drug discovery. Learn more: bit.ly/3PMIYEQ

This week at #AACR25, we will present preclinical data on our highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader in HR-positive/HER2-negative breast cancer. CSO Sharon Townson comments on our innovative approach: bit.ly/3GFQDU4

At #AACR25? Join Nina Ilic-Widlund and Sofia Gkountela as they present the latest preclinical data on Monte Rosa’s novel molecular glue degrader for the potential treatment of HR-positive/HER2-negative breast cancer. Read the full press release here: bit.ly/3GFQDU4

What if we could map the surface features that make a protein degradable? At Monte Rosa, we’re doing just that – creating ‘glueprints’ to rationally design molecular glue degraders for previously undruggable targets. Our latest preprint explains how: bit.ly/4d3vxex

Proud to share our invited review in Trends in Biotechnology on using machine learning to predict de novo protein-protein interactions – pushing beyond nature’s blueprint to enable new advances in drug discovery and protein engineering. Congrats to the team: bit.ly/3Zy4thY

At Monte Rosa, we're advancing high-throughput proteomics to accelerate target ID for molecular glue degraders – and sharing our latest at #ASMS2025. Join us to learn more about how our proprietary platform is driving speed, depth & reproducibility in MGD drug discovery.

Please join us as our CEO Markus Warmuth participates in a fireside chat today at the Jefferies Global Healthcare Conference in New York, sharing insight into our recent progress and strategic priorities: bit.ly/4kSIieF #JefferiesHealthcare

Pleased to announce FDA clearance of our IND application for MRT-8102, a NEK7-directed molecular glue degrader designed to target inflammatory diseases driven by the NLRP3 inflammasome, IL-1β, and IL-6. Learn more: bit.ly/4l0ky8C

Monte Rosa presents new preclinical data on our NEK7-directed molecular glue degrader, MRT-8102, this week at #EULAR2025. These findings highlight the potential of NEK7-targeting MGDs as a promising therapeutic approach for multiple inflammatory diseases.

Our AI-powered QuEEN discovery engine has delivered a pipeline of novel molecular glue degraders that selectively degrade high-potential, hard-to-drug proteins, offering new treatment possibilities in key therapeutic areas. Explore our pipeline: bit.ly/3SU3apW

Today, we're presenting new data on MRT-6160 – a first-in-class, rationally designed MGD that selectively targets VAV1 – supporting its potential to benefit patients with neuroinflammatory diseases and other immune-mediated conditions. bit.ly/3HXZa5F #FOCIS2025

Today, we published new discoveries in a Science Magazine cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine: bit.ly/4eBn8Q

Grateful to Sally Church for her incisive review of our recent Science Magazine manuscript, capturing its significance — from target space expansion to pharmacologic implications to the evolving therapeutic landscape. Paper here: bit.ly/4koxZ1m

Exceptional individuals united as a team are critical to our success. Join us on our epic journey from one of two base camps – Boston and Basel. To view open positions, visit: bit.ly/4f2SXSj